

Expert Information

from the Working Group on Hygiene

Murine Norovirus

Status: April 2014

Author:

Michael Mähler,
Hannover

Exclusion of Liability

The use of the booklets (publications) and statements of GV-SOLAS and the implementation of the information contained therein are expressly at your own risk. GV-SOLAS and the authors cannot be held responsible for any accidents or damage of any kind arising from the use of the publication (e.g. due to lack of safety information), irrespective of their legal grounds. Liability claims against GV-SOLAS and the authors for any damage of material or immaterial nature caused by the use or non-use of the information or the use of incorrect and/or incomplete information are generally excluded. Legal and damage claims are therefore excluded.

The publication including all content has been compiled with the greatest care. However, GV-SOLAS and the authors assume no liability for the topicality, correctness, completeness of quality of the information provided. Printing errors and false information cannot be completely excluded. The GV-SOLAS and the authors do not assume any liability for the topicality, correctness and completeness of the contents of the book, as well as for printing errors. GV SOLAS and the authors cannot assume any legal responsibility or liability in any nature for any incorrect information and the resulting consequences.

Only the owners of the websites printed in these publications are responsible for the contents of these Internet pages. GV-SOLAS and the authors therefore expressly dissociate themselves from all third-party contents. Liable in accordance with the German press laws: the Board of Directors of GV-SOLAS.

Noroviruses are nonenveloped RNA viruses with high environmental resistance and belong to the family Caliciviridae, genus Norovirus. They were first identified after an outbreak of acute gastroenteritis at a school in Norwalk/Ohio (USA) in 1968 and cause about 90% of nonbacterial epidemic gastroenteritis in humans. Noroviruses found in animals include bovine, porcine, canine, feline and murine noroviruses. Noroviruses are not known to cross species.

The first norovirus to infect mice was described in 2003 (1). Experimental inoculation studies with this murine norovirus (MNV-1) show that duration of infection and disease manifestation vary depending on the mouse strain (1-3). In immunocompetent strains, MNV-1 infection is variable in length (e.g. ≥ 7 -14 days in 129S6 mice, ≥ 5 weeks in Hsd:ICR mice) and does not induce clinical signs. Infection is associated with mild histopathological alterations in the small intestine (increase in inflammatory cells) and spleen (red pulp hypertrophy and white pulp activation) of 129S6 mice. However, infection can cause lethal systemic disease (encephalitis, vasculitis, meningitis, hepatitis and pneumonia) in certain immunodeficient lines with defects in the innate immune system (interferon- $\alpha\beta\gamma$ receptor-/- and Stat1-/- mice) or persist without symptoms in mice with defects in the acquired immune system (≥ 90 days in Rag1-/- und Rag2-/- mice). These findings indicate that components of the innate immune system are critical for resistance to MNV-1 induced disease. Consistent with this hypothesis, Wobus et al. (4) demonstrated that MNV-1 replicates in macrophages and dendritic cells. Meanwhile, many additional strains of MNV with diverse biological properties were isolated (5-9). An analysis of 26 MNV isolates revealed 15 distinct MNV strains that comprise a single genogroup and serotype (6).

Experimental inoculation studies show that several MNV strains are able to persist in various tissues (small intestine, caecum, mesenteric lymph

genogroup and serotype (6). Experimental inoculation studies show that several MNV strains are able to persist in various tissues (small intestine, caecum, mesenteric lymph node, spleen) of immunocompetent (C57BL/6), Hsd:ICR, Jcl:ICR) and immunodeficient (C.B-17-Prkdcscid) mice with viral shedding in faeces for the duration of at least 35-60 days (5, 6, 10). MNV is transmitted via the faecal-oral route and is efficiently transferred to sentinel mice by soiled bedding (11, 12).

Embryo transfer (11) and hysterectomy (10) are effective means of eliminating MNV from mouse colonies. Since 1- to 3-day-old pups are resistant to infection, elimination of MNV may also be achieved by transferring neonates from infected dams to uninfected foster dams ("cross fostering") (13-15). This transfer should ideally be performed within 24 hours after birth.

MNV infection can be detected directly by RT-PCR on faecal pellets or tissue specimens (see above) and indirectly by serology (1-3, 5, 10, 16). Detection is facilitated by high stability of MNV RNA in faeces (at least 2 weeks at room temperature) (12) and by broad serological cross-reactivity among different strains of MNV (5, 6). Health surveillance data from North America (2, 17), Western Europe (16, 18, 19) Australasia (20) and Japan (21, 22) demonstrate a high prevalence of MNV infections in laboratory mice. In the hitherto largest survey (17), 32.4% of 44,876 mouse serum samples examined had antibodies against MNV. Various studies indicate that MNV is also circulating in wild rodents (23-26).

The impact of MNV on animal experiments remains to be evaluated. Recent studies show that MNV is immunomodulatory and may alter disease phenotypes in mouse models of inflammatory bowel disease (27-29). Furthermore, MNV modestly lowered the CD8 T cell response to murine cytomegalovirus infection in BALB/c and C57BL/6 mice (30), increased the duration of faecal mouse parvovirus shedding in BALB/cByJ and C57BL/6J mice (31), and increased atherosclerotic lesion size in B6.129S7-Ldlrtm1Her mice fed a high-fat diet (32). Other studies did not reveal any impact of MNV on experimental outcomes in mice (33-37).

In norovirus research, MNV is used as a model system to study aspects of norovirus biology and pathogenesis in vitro and in vivo (38, 39). It further serves as a surrogate for (non-cultivable) human noroviruses to evaluate chemical and physical methods of inactivation (40, 41).

Literature:

1. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW. 2003. STAT1-dependent innate immunity to a Norwalk-like virus. *Science* 299:1575-8.
2. Hsu CC, Wobus CE, Steffen EK, Riley LK, Livingston RS. 2005. Development of a microsphere-based serologic multiplexed fluorescent immunoassay and a reverse transcriptase PCR assay to detect murine norovirus 1 infection in mice. *Clin Diagn Lab Immunol* 12:1145-51.
3. Mumphrey SM, Changotra H, Moore TN, Heimann-Nichols ER, Wobus CE, Reilly MJ, Moghadamfalahi M, Shukla D, Karst SM. 2007. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. *J Virol* 81:3251-63.
4. Wobus CE, Karst SM, Thackray LB, Chang K-O, Sosnovtsev SV, Belliot G, Krug A, Mackenzie JM, Green KY, Virgin HW. 2004. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. *PLoS Biol* 2:2076-84.
5. Hsu CC, Riley LK, Wills HM, Livingston RS. 2006. Persistent infection with and serologic cross-reactivity of three novel murine noroviruses. *Comp Med* 56:247-51.
6. Thackray LB, Wobus CE, Chachu KA, Liu B, Alegre ER, Henderson KS, Kelley ST, Virgin HW. 2007. Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. *J Virol* 81:10460-73.
7. Kim M, Lee H, Chang K-O, Ko G. 2010. Molecular characterization of murine norovirus isolates from South Korea. *Virus Res* 147:1-6.
8. Barron EL, Sosnovtsev SV, Bok K, Prikhodko V, Sandoval-Jaime C, Rhodes CR, Hasenkrug K, Carmody AB, Ward JM, Perdue K, Green KY. 2011. Diversity of murine norovirus strains isolated from asymptomatic mice of different genetic backgrounds within a single U.S. Research Institute. *PLoS One* 6(6):e21435. doi: 10.1371/journal.pone.0021435.
9. Zhu S, Regev D, Watanabe M, Hickman D, Moussatche N, Jesus DM, Kahan SM, Naphine S, Brierley I, Hunter RN, Devabhaktuni D, Jones MK, Karst SM. 2013. Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains. *PLoS Pathog* 9(9):e1003592. doi: 10.1371/journal.ppat.1003592.
10. Goto K, Hayashimoto N, Yasuda M, Ishida T, Kameda S, Takakura A, Itoh T. 2009. Molecular detection of murine norovirus from experimentally and spontaneously infected mice. *Exp Anim* 58:135-40.
11. Perdue KA, Green KY, Copeland M, Barron E, Mandel M, Faucette LJ, Williams EM, Sosnovtsev SV, Elkins WR, Ward JM. 2007. Naturally occurring murine norovirus infection in a large research institution. *J Am Assoc Lab Anim Sci* 46:39-46.
12. Manuel CA, Hsu CC, Riley LK, Livingston RS. 2008. Soiled-bedding sentinel detection of murine norovirus 4. *J Am Assoc Lab Anim Sci* 47:31-6.
13. Artwohl JE, Purcell JE, Fortman JD. 2008. The use of cross-foster rederivation to eliminate murine norovirus, *Helicobacter* spp., and murine hepatitis virus from a mouse colony. *J Am Assoc Lab Anim Sci* 47:19-24.
14. Compton SR. 2008. Prevention of murine norovirus infection in neonatal mice by fostering. *J Am Assoc Lab Anim Sci* 47:25-30.
15. Buxbaum LU, DeRitis PC, Chu N, Conti PA. 2011. Eliminating murine norovirus by cross-fostering. *J Am Assoc Lab Anim Sci* 50:495-9.
16. Müller B, Klemm U, Mas Marques A, Schreier E. 2007. Genetic diversity and recombination of murine noroviruses in immunocompromised mice. *Arch Virol* 152:1709-19.
17. Pritchett-Corning KR, Cosentino J, Clifford CB. 2009. Contemporary prevalence of infectious agents in laboratory mice and rats. *Lab Anim* 43:165-73.

GV-SOLAS, Working Group on Hygiene, Murine Norovirus

18. Mähler M, Köhl W. 2009. A serological survey to evaluate contemporary prevalence of viral agents and *Mycoplasma pulmonis* in laboratory mice and rats in western Europe. *Lab Anim (NY)* 38(5):161-5.
19. Mahabir E, Bensch S, Brielmeier M, Schmidt J. 2009. Prevalence of murine norovirus in a breeding and experimental mouse facility. *Proceedings of the Tenth FELASA Symposium and the XIV ICLAS General Assembly & Conference*, p. 88-90.
20. McInnes EF, Rasmussen L, Fung P, Auld AM, Alvarez L, Lawrence DA, Quinn ME, del Fierro GM, Vassallo BA, Stevenson R. 2011. Prevalence of viral, bacterial and parasitological diseases in rats and mice used in research environments in Australasia over a 5-y period. *Lab Anim (NY)* 40(11):341–50.
21. Hayashimoto N, Morita H, Ishida T, Yasuda M, Kameda S, Uchida R, Tanaka M, Ozawa M, Sato A, Takakura A, Itoh T, Kagiya N. 2013. Current microbiological status of laboratory mice and rats in experimental facilities in Japan. *Exp Anim* 62:41-8.
22. Ohsugi T, Matsuura K, Kawabe S, Nakamura N, Kumar JM, Wakamiya M, Morikawa S, Urano T. 2013. Natural infection of murine norovirus in conventional and specific pathogen-free laboratory mice. *Front Microbiol* 4:12. doi: 10.3389/fmicb.2013.00012.
23. Parker SE, Malone S, Bunte RM, Smith AL. 2009. Infectious diseases in wild mice (*Mus musculus*) collected on and around the University of Pennsylvania (Philadelphia) campus. *Comp Med* 59:424-30.
24. Farkas T, Fey B, Keller G, Martella V, Egyed L. 2012. Molecular detection of murine noroviruses in laboratory and wild mice. *Vet Microbiol* 160:463-7.
25. Smith DB, McFadden N, Blundell RJ, Meredith A, Simmonds P. 2012. Diversity of murine norovirus in wild-rodent populations: species-specific associations suggest an ancient divergence. *J Gen Virol* 93:259-66.
26. Tsunesumi N, Sato G, Iwasa M, Kabeya H, Maruyama S, Tohya Y. 2012. Novel murine norovirus-like genes in wild rodents in Japan. *J Vet Med Sci* 74:1221-4.
27. Lencioni KC, Seamons A, Treuting PM, Maggio-Price L, Brabb T. 2008. Murine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease. *Comp Med* 58:522-33.
28. Cadwell K, Patel KK, Maloney NS, Liu T-C, Ng ACY, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW. 2010. Virus-plus-susceptibility gene interaction determines Crohn's disease gene *Atg16L1* phenotypes in intestine. *Cell* 141:1135-45.
29. Basic M, Keubler LM, Büttner M, Achard M, Breves G, Schröder B, Smoczek A, Jörns A, Wedekind D, Zschemisch N-H, Günther C, Neumann D, Lienenklaus S, Weiss S, Hornef MW, Mähler M, Bleich A. 2014. Norovirus triggered microbiota-driven mucosal inflammation in interleukin 10-deficient mice. *Inflamm Bowel* 20(3):431-43. doi: 10.1097/O1.MIB.0000441346.86827.ed.
30. Doom CM, Turula HM, Hill AB. 2009. Investigation of the impact of the common animal facility contaminant murine norovirus on experimental murine cytomegalovirus infection. *Virology* 392:153-61.
31. Compton SR, Paturzo FX, Macy JD. 2010. Effect of murine norovirus infection on mouse parvovirus infection. *J Am Assoc Lab Anim Sci* 49:11-21.
32. Paik J, Fierce Y, Mai P-O, Phelps SR, McDonald T, Treuting P, Drivdahl R, Brabb T, LeBoeuf R, O'Brien KD, Maggio-Price L. 2011. Murine norovirus increases atherosclerotic lesion size and macrophages in *Ldlr*^{-/-} mice. *Comp Med* 61:330-8.
33. Hensley SE, Pinto AK, Hickman HD, Kastenmayer RJ, Bennink JR, Virgin HW, Yewdell JW. 2009. Murine norovirus infection has no significant effect on adaptive immunity to vaccinia virus or influenza A virus. *J Virol* 83:7357-60.
34. Paik J, Fierce Y, Drivdahl R, Treuting PM, Seamons A, Brabb T, Maggio-Price L. 2010. Effects of murine norovirus on a mouse model of diet-induced obesity and insulin resistance. *Comp Med* 60:189-95.
35. Higgins PD, Johnson LA, Sauder K, Moons D, Blanco L, Taube S, Wobus CE. 2011. Transient or persistent norovirus infection does not alter the pathology of *Salmonella typhimurium* induced intestinal inflammation and fibrosis in mice. *Comp Immunol Microbiol Infect Dis* 34:247-57.

GV-SOLAS, Working Group on Hygiene, Murine Norovirus

36. Lencioni KC, Drivdahl R, Seamons A, Treuting PM, Brabb T, Maggio-Price L. 2011. Lack of effect of murine norovirus infection on a mouse model of bacteria-induced colon cancer. *Comp Med* 61:129-26.
37. Nelson AM, Elftman MD, Pinto AK, Baldrige M, Hooper P, Kuczynski J, Petrosino JF, Young VB, Wobus CE. 2013. Murine norovirus infection does not cause major disruptions in the murine intestinal microbiota. *Microbiome* 1(1):7. doi: 10.1186/2049-2618-1-7.
38. Wobus CE, Thackray LB, Virgin HW. 2006. Murine norovirus: a model system to study norovirus biology and pathogenesis. *J Virol* 80:5104-12.
39. Thorne LG, Goodfellow G. 2014. Norovirus gene expression and replication. *J Gen Virol* 95:278-91.
40. Hoelzer K, Fanaselle W, Pouillot R, Van Doren JM, Dennis S. 2013. Virus inactivation on hard surfaces or in suspension by chemical disinfectants: systematic review and meta-analysis of norovirus surrogates. *J Food Prot* 76:1006-16.
41. Nims R, Plavsic M. 2013. Inactivation of caliciviruses. *Pharmaceuticals (Basel)* 6:358-92.